

DUR+ Preferred Cytokine and CAM Antagonists criteria

NOTE: Non-preferred agents require clinical review

Actemra (tocilizumab) – Age specific indications:

- Age 2 years and older **AND**
- Diagnosis of juvenile arthritis (JIA)

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of lung disease with systemic sclerosis (SSc-ILD) **OR**
- Diagnosis of giant cell arteritis
- Other indications require clinical review
- Non-preferred Actemra Actpen requires clinical review

Avsola (infliximab-axxq) – Age specific indications:

- Age 6 years and older **AND**
- Diagnosis of Crohn's disease **OR**
- Diagnosis of ulcerative colitis

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of plaque psoriasis (PsO) **OR**
- Diagnosis of psoriatic arthritis (PsA) **OR**
- Diagnosis of ankylosing spondylitis (AS)

Enbrel (etanercept) – Age specific indications:

- Age 2 years and older **AND**
- Diagnosis of juvenile arthritis (JIA) **OR**
- Diagnosis of juvenile psoriatic arthritis (PsA)

- Age 4 years and older **AND**
- Diagnosis of plaque psoriasis (PsO)

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of psoriatic arthritis (PsA) **OR**
- Diagnosis of ankylosing spondylitis (AS)

Humira (adalimumab) – Age specific indications:

- Age 2 years and older **AND**
- Diagnosis of juvenile idiopathic arthritis (JIA) **OR**
- Diagnosis of uveitis (UV)

- Age 5 years and older **AND**
- Diagnosis of ulcerative colitis (UC)
- Age 6 years and older **AND**
- Diagnosis of Crohn's disease (CD)

- Age 12 years and older **AND**

- Diagnosis of hidradenitis suppurativa (HS)

Humira (cont'd)

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of plaque psoriasis (PsO) **OR**
- Diagnosis of psoriatic arthritis (PsA) **OR**
- Diagnosis of ankylosing spondylitis (AS)

Kineret (anakinra) – Age specific indications:

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA)
- Other indications require clinical review

Olumiant (baricitinib) – Age specific indications:

- Age 18 years and older **AND**
- Diagnosis of alopecia areata (AA)
- Other indications require clinical review

Orencia (etanercept) – Age specific indications:

- Age 2 years and older **AND**
- Diagnosis of juvenile arthritis (JIA) **OR**
- Diagnosis of psoriatic arthritis (PsA)
- Other indication requires clinical review

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA)
- Non-preferred Orencia syringe requires clinical review

Otezla (apremilast) – Age specific indications:

- Age 6 years and older **AND**
- Diagnosis of plaque psoriasis (PsO)
- Age 18 years and older **AND**
- Diagnosis of Bechet's disease **OR**
- Diagnosis of psoriatic arthritis (PsA)

Rinvoq (upadacitinib):

- History of 3 claims with preferred TNF Inhibitor Avsola, Enbrel, Humira or Simponi
- **OR**
- History of 1 claim with Rinvoq in the past **AND**
- NO history of concomitant therapy in the past 30 days with any of the following:
 - A different JAK Inhibitor
 - A different biologic
 - Immunosuppressant azathioprine or cyclosporine

Simponi (golimumab) – Age specific indications:

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of psoriatic arthritis (PsA) **OR**
- Diagnosis of ankylosing spondylitis (AS) **OR**
- Diagnosis of ulcerative colitis
- Non-preferred Simponi Aria requires clinical review

Taltz (izekizumab) – Age specific indications:

Taltz 20 mg, 40 mg and 80 mg

- Age 6 **AND**
- Diagnosis of plaque psoriasis (PsO)

Taltz 80 mg

- Age 18 years and older **AND**
- Diagnosis of psoriatic arthritis (PsA) **OR**
- Diagnosis of ankylosing spondylitis (AS) **OR**
- Diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA)

Tyenne (tocilizumab) – Age specific indications:

- Age 2 years and older **AND**
- Diagnosis of juvenile arthritis (JIA)

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of giant cell arteritis
- Non-preferred Tyenne autoinject requires clinical review

Xeljanz IR (tofacitinib) – Any of the following:

- Age 18 years and older **AND**
- Diagnosis of rheumatoid arthritis (RA) **OR**
- Diagnosis of ulcerative colitis (UC) **OR**
- Diagnosis of plaque psoriasis (PsO) **OR**
- Diagnosis of ankylosing spondylitis (AS)
- Non-preferred Xeljanz oral solution and Xeljanz XR require clinical review

Preferred methotrexate does not require prior authorization